Abstract:The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes (T2D). The development of short- and then long-acting GLP-1 receptor agonists (GLP-1RAs) followed. Our article charts the discovery and development of the long-acting GLP-1 analogs liraglutide and, subsequently, semaglutide. We examine the chemistry employed in designing liraglutide and semaglutide, the human and non-human studies used to investigate their cellular targets and pharmacological effects, and ongoing investigations into new applications and formulations of these drugs. Reversible binding to albumin was used for the systemic protraction of liraglutide and semaglutide, with optimal fatty acid and linker combinations identified to maximize albumin binding while maintaining GLP-1 receptor (GLP-1R) potency. GLP-1RAs mediate their effects via this receptor, which is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. GLP-1Rs in the pancreas and brain have been shown to account for the respective improvements in glycemic control and body weight that are evident with liraglutide and semaglutide. Both liraglutide and semaglutide also positively affect cardiovascular (CV) outcomes in individuals with T2D, although the precise mechanism is still being explored. Significant weight loss, through an effect to reduce energy intake, led to the approval of liraglutide (3.0 mg) for the treatment of obesity, an indication currently under investigation with semaglutide. Other ongoing investigations with semaglutide include the treatment of non-alcoholic fatty liver disease (NASH) and its use in an oral formulation for the treatment of T2D. In summary, rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes. Furthermore, the development of an oral formulation for semaglutide may provide individuals with additional benefits in relation to treatment adherence. In addition to T2D, liraglutide is used in the treatment of obesity, while semaglutide is currently under investigation for use in obesity and NASH.

Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment

Liraglutide-Loaded Multivesicular Liposome As A Sustained-Delivery Reduces Blood Glucose in Sd Rats with Diabetes

A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes

Controlled release of liraglutide using thermogelling polymers in treatment of diabetes

Injectable and Thermosensitive Hydrogel Containing Liraglutide As a Long-Acting Antidiabetic System

Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.

An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits

Sustained release of GLP-1 analog from γ-PGA-PAE copolymers for management of type 2 diabetes

Preparation, Characterization, and Pharmacodynamics of Exenatide-Loaded Poly(DL-lactic-co-glycolic Acid) Microspheres

641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide

781-P: Sustained-Release Formulation Development and Preclinical Evaluations of Monthly or Bimonthly Injectable Semaglutide and Tirzepatide

Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system

Effects of Liraglutide on Glycemic Gontrol in Metformin-Treated Patients with Type 2 Diabetes Mellitus

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.

Exenatide-loaded PLGA Microspheres with Improved Glycemic Control: in Vitro Bioactivity and in Vivo Pharmacokinetic Profiles after Subcutaneous Administration to SD Rats.

Bioactive spermidine nanoparticles for effective cardiovascular recovery and diabetic therapy

In Vitro and in Vivo Sustained Release of Exenatide from Vesicular Phospholipid Gels for Type II Diabetes

Clinical efficacy and safety of Liraglutide in the treatment of obese or overweight patients with different duration of T2DM

78-LB: PK Studies in Rats and Minipigs of GB-7001, a Novel Monthly Microsphere Formulation Containing High Drug Content of Semaglutide

The Discovery and Development of Liraglutide and Semaglutide

The limitation of lipidation: conversion of semaglutide from once-weekly to once-monthly dosing